Direxion Daily Semiconductor Bear 3X Shares vs GeneDx Holdings Corp — how do they compare? Direxion Daily Semiconductor Bear 3X Shares trades at $34.39 (market cap $1.96B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Direxion Daily Semiconductor Bear 3X Shares and GeneDx Holdings Corp are close in size by market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Direxion Daily Semiconductor Bear 3X Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily Semiconductor Bear 3X Shares for 11 Days and GeneDx Holdings Corp for 19 Days on average.
| SOXS | WGS | |
|---|---|---|
Market Cap | $1.96B | $2.02B |
Volume | 113,512,541 | 734,640 |
Sector | Leveraged / Inverse | Health |
52-Week High | $988.00 | $167.51 |
52-Week Low | $29.62 | $34.51 |
Typical Hold Time | 11 Days | 19 Days |
Enterprise Value | — | $2.05B |
Signals from Pluang's Aura AI — not financial advice
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, surged 10.23% to $33.78 amid semiconductor sector volatility. The technical outlook remains bearish with moving averages signaling continued downward pressure, while oscillators show neutral momentum. Recent news highlights SOXS benefiting from semiconductor sell-offs, though analysts caution it's suited only for short-term tactical trades due to extreme volatility and structural decay inherent in leveraged inverse ETFs.
As a leveraged inverse ETF, SOXS carries significant risks including daily rebalancing costs and time decay, making it unsuitable for long-term holdings. The fund thrives during semiconductor downturns but faces headwinds from persistent AI hardware demand. Investors should recognize this as a speculative trading instrument rather than a fundamental investment vehicle.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →